ZYBERNO
Stock Report
Updated Jun 10, 2026

FINCH THERAPEUTICS GROUP, INC. (FNCH)

Healthcare • Over The Counter

$7.45

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
FINCH THERAPEUTICS GROUP, INC. (FNCH) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-61.4%)
Debt-to-Equity (Solvency Risk):CRITICAL (4.68x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-49.4%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

FINCH THERAPEUTICS GROUP, INC. (FNCH) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, FNCH generated -$22.50M in Owner Earnings. Capital was deployed as follows: $14.00K invested in capital expenditures. Reinvestment rate: 11.3%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:7.45
Market Cap:$11.96M

Valuation Multiples (2)

P/B Ratio:0.84x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$24.92M
B. Profitability Assessment

Return Metrics (5)

ROA:-23.9%
Reinvestment Rate:11.3%
Fundamental Growth Rate (g):-5.6%

Margin Analysis (1)

Ebitda Margin:-16,557.0%

Yield Metrics (2)

Earnings Yield:-$622.15
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:67.7%
Latest Earnings Filed:2024-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.87x
Quick Ratio:3.87x
Cash Ratio:3.59x

Leverage Analysis (3)

Debt To Equity Ttm:4.68x
Debt-to-Equity Ratio:4.68x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:12,817,000.00
Cash And Cash Equivalents:16,035,000.00
Long Term Debt:$26.90M
Net Debt:$12.95M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $107.00K
Linear Growth: -50.0%
📊 Click to view full FNCH Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$17.91M

Bottom Line Performance (3)

-$12.58M
Income Before Tax:-$12.58M
Ebitda Ttm:-17,716,000.00

Operating Expenses (5)

Operating Expenses:17,912,000.00
R And D Expense:7,199,000.00
Sga Expense:19,689,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:-16,557.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$45.58M
Current Assets:$17.28M
Ppe Net:507,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:31,357,000.00
Current Liabilities:4,462,000.00
Long Term Debt:$26.90M
Short Term Debt:$2.09M

Equity & Capital (3)

Equity:$14.22M
Retained Earnings:-$359.11M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:29,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:15,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$22.49M-$22.50M

Investment Activities (2)

Investing Cash Flow:$0.00
Capital Expenditures Ttm:-14,000.00

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:196,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-46.35
-$46.35
Earnings Per Share Ttm:-$7.83

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$19.62

Book Value & Capital (2)

Book Value Per Share:$8.85
Cash Per Share:9.99

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.00x
Working Capital Turnover Ttm:0.01x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:98.93
Cash Conversion Cycle:-2,096.93
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$22.50M

Damodaran Growth Analysis (2)

Reinvestment Rate:11.3%
Fundamental Growth Rate (g):-5.6%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:FNCH
Company Name:FINCH THERAPEUTICS GROUP, INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:Over The Counter
Country:Unknown

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.61M
Shares Outstanding Basic:1.61M
Shares Outstanding Diluted:1.61M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-10 15:08:23 UTC
Data Timestamp:2026-06-10T15:08:23.096422
Scroll to Top